Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009
Date:7/14/2009

arly 30%," said Steven W. King, president and CEO of Peregrine. "These accomplishments have allowed us to build significant value in our oncology clinical pipeline, to grow the value of our contract manufacturing business and to realize immediate value from our bavituximab anti-viral technology platform through our DTRA government contract. These achievements have created considerable momentum that we expect to maintain throughout the coming year."

Mr. King added, "We more than doubled our Avid contract manufacturing revenues and recorded more than $5 million in first-year revenues from a multi-year government contract to evaluate our bavituximab anti-viral platform for its broad spectrum potential to treat or prevent serious virus infections. At the same time, we advanced our bavituximab and Cotara clinical trials in FY 2009 while keeping R&D costs flat. These trials have already yielded very promising early results, and we are optimistic they will continue to yield positive results during the current fiscal year."

Mr. King continued, "This year we also made important progress in raising the profile of all three of our clinical programs among investors, potential partners and the medical community, and as a result, the pace of our partnering efforts has accelerated. Among the most significant developments driving this increased interest was the release of our first clinical data indicating that bavituximab may be a valuable new option for treating cancer. In three separate Phase II trials in combination with chemotherapy, bavituximab demonstrated encouraging signs of efficacy in patients with advanced breast cancer and advanced lung cancer. All three trials surpassed the requisite efficacy criteria for expansion of patient enrollment, which is now well underway. These trials, along with our Phase I bavituximab cancer study that recently completed patient enrollment, are helping to set the stage for advancing ba
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
7. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
8. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
9. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
10. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
11. ASCO Research Foundation Grant Will Support Study of Peregrines Bavituximab in Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... 2015 , ... “ Crack’em ” was featured on NewsWatch as part of ... consumers. Amanda Forstrom, a technology expert and special reporter for NewsWatch, conducted the review ... , Cooking can be a very messy experience, especially when cracking eggs. Cracking an ...
(Date:7/31/2015)... ... July 31, 2015 , ... Nutritional Products International, ... nutritional and wellness products, announced the addition of Vincent Aquilino to its Board ... isolated stretching and the prevention and rehabilitation of injuries, has spent the last ...
(Date:7/31/2015)... ... July 31, 2015 , ... Intellitec Solutions ... recent implementation of Microsoft Dynamics GP for a senior living facility in Maine. ... supporting senior living communities in 16 states. This further expansion was again a ...
(Date:7/31/2015)... ... July 31, 2015 , ... With the ... number of individuals who remain undiagnosed, treatment options for patients are becoming more ... traditional CPAP therapy due to its overall lack of comfort and highly invasive ...
(Date:7/30/2015)... ... July 31, 2015 , ... Reduce Human Error on the ... FDAnews and Ginette M. Collazo, Inc.**, Sept. 16-17, 2015 – Raleigh, NC, ... biologic and device firms reduce manufacturing errors by 50 percent or more, will ...
Breaking Medicine News(10 mins):Health News:Make Less Mess while Cooking with Crack’em 2Health News:NPI Welcomes Vincent Aquilino to Board of Directors 2Health News:Intellitec Solutions Expands Long term Care ERP Offerings to Maine 2Health News:Oravan Sleep Apnea Device Gains Traction in Sleep Industry 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4
... be entangled in a health controversy now in China. Scientists ... causing agent, in potato fries exceeds the limit in drinking ... times.// ,The Chinese Ministry of Health said that measures ... acrylamide in humans. ,In April, the Chinese Ministry of ...
... reduce men's deaths from heart disease - even when ... above finding holds good regardless of the cholesterol level ... risk of dying from cardiovascular disease if they are ... effect relationship with respect to cardiovascular disease discovered that ...
... have published the results of their work linking mutations in ... was published in the Journal of Medical Ethics. //Mutations in ... and ovarian cancer in women has now found to increase ... men. The results of the study also confirmed the relation ...
... women confirms previous studies showing that a high-protein diet ... high carbohydrate diet. Researchers have also demonstrated that when ... protein-rich diet is still more effective at reducing body ... interactive effect when a protein-rich diet is combined with ...
... obesity is severe like never before. The problem seems to ... from Tufts University this month proves, when it comes to ... ,''It's quite astounding -- this shows that we can't afford ... specialist involved with the initiative that brought the girls to ...
... had discovered that a single molecule is responsible for ... body. // ,By blocking the molecule’s anchoring ... to stave off the most common serious infection of ... childhood death and disability. The researchers’ findings appear in ...
Cached Medicine News:Health News:French Fries In Cancer Controversy In China 2Health News:A Protein-Rich Diet Combined With Exercise Found To Be More Effective In Weight Loss 2Health News:Early Awareness About Weight Management Needed To Tackle Lifelong Obesity 2
(Date:7/30/2015)... 2015  Medimetriks Pharmaceuticals, Inc. announced today that ... clinical study for Ozenoxacin, a novel bactericidal non-fluorinated ... exclusive U.S. rights to Ozenoxacin 1% cream.  ... centers with an emphasis on U.S. patients, involved ... and older with a clinical diagnosis of bullous ...
(Date:7/30/2015)... VIEJO, Calif. , July 30, 2015 /PRNewswire/ ... aspiring to eliminate all preventable hospitalization, recently received ... that its Remote Patient Intelligence (RPI) solution meets ... the FDA intends to exercise "Enforcement Discretion." ... "are not subject to further FDA regulatory requirements ...
(Date:7/30/2015)... /PRNewswire/ - Anything Technologies Media, Inc. (OTC:EXMT) has announced ... Solutions (FIGS), www.frontiergarden.com has been announced ... Manager for a My Compassion originated medical cannabis ... in Alaska.  The project will be funded through ... Partners. The first phase of the project, is ...
Breaking Medicine Technology:Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 2FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 3Frontier Indoor Garden Solutions announced as Horticultural Supplier and Project Manager for Alaskan Tribal Medical Marijuana Grow Facility 2Frontier Indoor Garden Solutions announced as Horticultural Supplier and Project Manager for Alaskan Tribal Medical Marijuana Grow Facility 3
... April 25, 2007-Labtec GmbH (Langenfeld,Germany), a specialty ... dose clinical study for their proprietary,Sufentanil transdermal ... announce the successful,completion of the second clinical ... this program was to complete this study ...
... 2007 - Columbia,Laboratories, Inc. (NASDAQ: CBRX) today ... analysis of the recently-completed,randomized, placebo-controlled, double-blind Phase ... for the prevention of,preterm birth in women ... weeks gestation has revealed a possible effect ...
Cached Medicine Technology:Labtec’s Next Generation Pain Patch Successful in Clinical,Studies 2Columbia Laboratories Reports Preliminary Findings from the Ongoing,Data Analysis of the Phase III Clinical Study of PROCHIEVE 8%,(progesterone gel) to Prevent Preterm Birth 2Columbia Laboratories Reports Preliminary Findings from the Ongoing,Data Analysis of the Phase III Clinical Study of PROCHIEVE 8%,(progesterone gel) to Prevent Preterm Birth 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: